(NASDAQ: ANL) Adlai Nortye's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.5%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.42%.
Adlai Nortye's earnings in 2026 is -$35,528,000.On average, 7 Wall Street analysts forecast ANL's earnings for 2026 to be -$35,952,241, with the lowest ANL earnings forecast at -$76,440,512, and the highest ANL earnings forecast at -$20,160,135. On average, 6 Wall Street analysts forecast ANL's earnings for 2027 to be -$45,324,303, with the lowest ANL earnings forecast at -$75,264,504, and the highest ANL earnings forecast at -$31,500,211.
In 2028, ANL is forecast to generate -$65,208,436 in earnings, with the lowest earnings forecast at -$105,840,708 and the highest earnings forecast at -$36,540,245.